Dr. Brown on the Importance of Genetic Testing in Ovarian Cancer

Video

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses the importance of genetic testing in patients with ovarian cancer.

There are a number of reasons why genetic testing could have an impact on patient outcomes. First, by detecting women with hereditary mutations, clinicians can identify those who are at risk for ovarian cancer and intervene before they ever get the disease. There is approximately a 95% reduction in risk if these patients are identified, Brown says. The other key component is that in patients who have ovarian cancer, genetic testing can help decide if their family members are also at risk. Additionally, if a patient’s mutation profile is identified, it helps the process of deciding which targeted therapy to use.

The implementation of PARP inhibitors in ovarian cancer has greatly improved outcomes for patients with BRCA mutations, Brown says.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center